Published in Cell on January 20, 2012
Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet (2013) 2.91
Cleaning up: ER-associated degradation to the rescue. Cell (2012) 2.08
Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nat Chem Biol (2013) 1.76
Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet (2014) 1.70
Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med (2014) 1.64
Modulation of the maladaptive stress response to manage diseases of protein folding. PLoS Biol (2014) 1.54
VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell (2013) 1.29
Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J (2012) 1.17
Pharmacological rescue of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) detected by use of a novel fluorescence platform. Mol Med (2012) 1.15
Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am J Respir Cell Mol Biol (2014) 1.10
Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules. Proc Natl Acad Sci U S A (2013) 1.05
Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain. EMBO Mol Med (2013) 1.04
Thermal instability of ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) channel function: protection by single suppressor mutations and inhibiting channel activity. Biochemistry (2012) 1.01
Revertant mutants modify, but do not rescue, the gating defect of the cystic fibrosis mutant G551D-CFTR. J Physiol (2014) 1.00
Deletion of Phenylalanine 508 in the First Nucleotide-binding Domain of the Cystic Fibrosis Transmembrane Conductance Regulator Increases Conformational Exchange and Inhibits Dimerization. J Biol Chem (2015) 0.97
Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol (2014) 0.94
A chaperone trap contributes to the onset of cystic fibrosis. PLoS One (2012) 0.93
From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell (2016) 0.92
Pharmacological chaperoning: a primer on mechanism and pharmacology. Pharmacol Res (2014) 0.92
Small heat shock proteins target mutant cystic fibrosis transmembrane conductance regulator for degradation via a small ubiquitin-like modifier-dependent pathway. Mol Biol Cell (2012) 0.91
Membrane protein stability can be compromised by detergent interactions with the extramembranous soluble domains. Protein Sci (2014) 0.91
Fixing cystic fibrosis by correcting CFTR domain assembly. J Cell Biol (2012) 0.90
Functional Rescue of F508del-CFTR Using Small Molecule Correctors. Front Pharmacol (2012) 0.90
Mechanisms of CFTR Folding at the Endoplasmic Reticulum. Front Pharmacol (2012) 0.90
Allosteric coupling between the intracellular coupling helix 4 and regulatory sites of the first nucleotide-binding domain of CFTR. PLoS One (2013) 0.89
Regulated recycling of mutant CFTR is partially restored by pharmacological treatment. J Cell Sci (2013) 0.88
Annotating DNA variants is the next major goal for human genetics. Am J Hum Genet (2014) 0.87
Cystic fibrosis transmembrane conductance regulator (ABCC7) structure. Cold Spring Harb Perspect Med (2013) 0.87
New and emerging targeted therapies for cystic fibrosis. BMJ (2016) 0.87
CFTR potentiators partially restore channel function to A561E-CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-CFTR. Br J Pharmacol (2014) 0.86
Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors. Pediatr Pulmonol (2015) 0.85
Rescue of murine F508del CFTR activity in native intestine by low temperature and proteasome inhibitors. PLoS One (2012) 0.84
Restoration of NBD1 thermal stability is necessary and sufficient to correct ∆F508 CFTR folding and assembly. J Mol Biol (2014) 0.82
Rescue of NBD2 mutants N1303K and S1235R of CFTR by small-molecule correctors and transcomplementation. PLoS One (2015) 0.81
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR): CLOSED AND OPEN STATE CHANNEL MODELS. J Biol Chem (2015) 0.81
A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator. FASEB J (2015) 0.81
Bithiazole correctors rescue CFTR mutants by two different mechanisms. Biochemistry (2013) 0.80
Interference with ubiquitination in CFTR modifies stability of core glycosylated and cell surface pools. Mol Cell Biol (2014) 0.80
Correcting the cystic fibrosis disease mutant, A455E CFTR. PLoS One (2014) 0.79
Hallmarks of therapeutic management of the cystic fibrosis functional landscape. J Cyst Fibros (2015) 0.79
Pharmacological Correctors of Mutant CFTR Mistrafficking. Front Pharmacol (2012) 0.79
Channel Gating Regulation by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) First Cytosolic Loop. J Biol Chem (2015) 0.78
Rescuing ΔF508 CFTR with trimethylangelicin, a dual-acting corrector and potentiator. Am J Physiol Lung Cell Mol Physiol (2014) 0.78
Impact of the F508del mutation on ovine CFTR, a Cl- channel with enhanced conductance and ATP-dependent gating. J Physiol (2015) 0.78
ABCG2: the molecular mechanisms of urate secretion and gout. Am J Physiol Renal Physiol (2015) 0.78
Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med (2016) 0.77
Development of CFTR Structure. Front Pharmacol (2012) 0.77
Targeted proteomic quantitation of the absolute expression and turnover of cystic fibrosis transmembrane conductance regulator in the apical plasma membrane. J Proteome Res (2014) 0.77
Longevity and plasticity of CFTR provide an argument for noncanonical SNP organization in hominid DNA. PLoS One (2014) 0.77
Enhancing the Potency of F508del Correction: A Multi-Layer Combinational Approach to Drug Discovery for Cystic Fibrosis. J Pharmacol Clin Toxicol (2013) 0.77
Rescuing Trafficking Mutants of the ATP-binding Cassette Protein, ABCA4, with Small Molecule Correctors as a Treatment for Stargardt Eye Disease. J Biol Chem (2015) 0.77
Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy. Am J Physiol Lung Cell Mol Physiol (2016) 0.77
The Intergenic Recombinant HLA-B∗46:01 Has a Distinctive Peptidome that Includes KIR2DL3 Ligands. Cell Rep (2017) 0.77
Combination of Correctors Rescue ΔF508-CFTR by Reducing Its Association with Hsp40 and Hsp27. J Biol Chem (2015) 0.76
Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis Mutation. Sci Rep (2015) 0.76
Non-native Conformers of Cystic Fibrosis Transmembrane Conductance Regulator NBD1 Are Recognized by Hsp27 and Conjugated to SUMO-2 for Degradation. J Biol Chem (2015) 0.76
Functional reconstitution and channel activity measurements of purified wildtype and mutant CFTR protein. J Vis Exp (2015) 0.76
Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis. PLoS One (2016) 0.76
Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry. Chembiochem (2015) 0.76
Pharmacogenomics: mapping monogenic mutations to direct therapy. J Clin Invest (2012) 0.75
Specific stabilization of CFTR by phosphatidylserine. Biochim Biophys Acta (2016) 0.75
Two Small Molecules Restore Stability to a Sub-population of the Cystic Fibrosis Transmembrane conductance Regulator with the Predominant Disease-causing Mutation. J Biol Chem (2017) 0.75
Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy. Protein Sci (2016) 0.75
Stabilization of Nucleotide Binding Domain Dimers Rescues ABCC6 Mutants Associated with Pseudoxanthoma Elasticum. J Biol Chem (2016) 0.75
CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis. Front Pharmacol (2016) 0.75
Attenuation of Phosphorylation-dependent Activation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) by Disease-causing Mutations at the Transmission Interface. J Biol Chem (2016) 0.75
Analysis of cystic fibrosis-associated P67L CFTR illustrates barriers to personalized therapeutics for orphan diseases. JCI Insight (2016) 0.75
Decoding F508del misfolding in cystic fibrosis. Biomolecules (2014) 0.75
Biophysical Approaches Facilitate Computational Drug Discovery for ATP-Binding Cassette Proteins. Int J Med Chem (2017) 0.75
Complement yourself: Transcomplementation rescues partially folded mutant proteins. Biophys Rev (2014) 0.75
Strategies for the etiological therapy of cystic fibrosis. Cell Death Differ (2017) 0.75
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res (1997) 665.31
Clustal W and Clustal X version 2.0. Bioinformatics (2007) 126.47
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science (1989) 40.22
Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J (1982) 38.14
Jalview Version 2--a multiple sequence alignment editor and analysis workbench. Bioinformatics (2009) 31.84
The Jalview Java alignment editor. Bioinformatics (2004) 21.74
Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell (1990) 9.21
Evolutionarily conserved pathways of energetic connectivity in protein families. Science (1999) 9.12
Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature (1992) 8.47
PROMALS3D: a tool for multiple protein sequence and structure alignments. Nucleic Acids Res (2008) 7.16
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med (2010) 6.23
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A (2009) 5.72
AL2CO: calculation of positional conservation in a protein sequence alignment. Bioinformatics (2001) 4.79
Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature (1990) 4.26
Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest (2005) 4.19
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A (2011) 3.87
Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol (2006) 3.59
Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J (2003) 3.35
CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature (2005) 3.24
Co-evolution of proteins with their interaction partners. J Mol Biol (2000) 3.23
Evolutionary information for specifying a protein fold. Nature (2005) 3.23
The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat Struct Mol Biol (2004) 3.16
Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet (2005) 2.80
Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. J Biol Chem (2004) 2.66
Influence of conservation on calculations of amino acid covariance in multiple sequence alignments. Proteins (2004) 2.62
Protein solubility and folding monitored in vivo by structural complementation of a genetic marker protein. Nat Biotechnol (2001) 2.60
Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett (2007) 2.56
Side chain and backbone contributions of Phe508 to CFTR folding. Nat Struct Mol Biol (2004) 2.43
On the mechanism of MgATP-dependent gating of CFTR Cl- channels. J Gen Physiol (2003) 2.39
The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci (2004) 2.20
Mapping pathways of allosteric communication in GroEL by analysis of correlated mutations. Proteins (2002) 2.13
Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation. Chem Biol (2008) 1.97
Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem Biol (2011) 1.92
Identification of revertants for the cystic fibrosis delta F508 mutation using STE6-CFTR chimeras in yeast. Cell (1993) 1.72
Evolution of ATP-binding cassette transporter genes. Curr Opin Genet Dev (1995) 1.72
Protein co-evolution, co-adaptation and interactions. EMBO J (2008) 1.65
PROMALS3D web server for accurate multiple protein sequence and structure alignments. Nucleic Acids Res (2008) 1.58
Localization and suppression of a kinetic defect in cystic fibrosis transmembrane conductance regulator folding. J Biol Chem (1997) 1.57
A perturbation-based method for calculating explicit likelihood of evolutionary co-variance in multiple sequence alignments. Bioinformatics (2004) 1.57
Slc26a6 regulates CFTR activity in vivo to determine pancreatic duct HCO3- secretion: relevance to cystic fibrosis. EMBO J (2006) 1.56
Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms. Proc Natl Acad Sci U S A (2006) 1.56
The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J Biol Chem (2010) 1.55
Alteration of the cystic fibrosis transmembrane conductance regulator folding pathway. J Biol Chem (1996) 1.52
Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry. J Mol Biol (2009) 1.49
Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator delta f508. J Biol Chem (2002) 1.44
Correction of the Delta phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine. Mol Pharmacol (2010) 1.36
Permeation through the CFTR chloride channel. J Exp Biol (2000) 1.35
Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis. Protein Sci (2010) 1.28
Mutation of R555 in CFTR-delta F508 enhances function and partially corrects defective processing. Receptors Channels (1996) 1.27
Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant. Protein Eng Des Sel (2010) 1.26
Normal gating of CFTR requires ATP binding to both nucleotide-binding domains and hydrolysis at the second nucleotide-binding domain. Proc Natl Acad Sci U S A (2004) 1.26
Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol (2007) 1.25
Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide-binding domain 1. Protein Sci (2010) 1.25
The primary folding defect and rescue of ΔF508 CFTR emerge during translation of the mutant domain. PLoS One (2010) 1.17
Localization studies of rare missense mutations in cystic fibrosis transmembrane conductance regulator (CFTR) facilitate interpretation of genotype-phenotype relationships. Hum Mutat (2008) 1.15
Building an understanding of cystic fibrosis on the foundation of ABC transporter structures. J Bioenerg Biomembr (2007) 1.14
The cystic fibrosis transmembrane conductance regulator. Effects of the most common cystic fibrosis-causing mutation on the secondary structure and stability of a synthetic peptide. J Biol Chem (1992) 1.11
Coevolution at protein complex interfaces can be detected by the complementarity trace with important impact for predictive docking. Proc Natl Acad Sci U S A (2008) 1.05
Cystic fibrosis with three mutations in the cystic fibrosis transmembrane conductance regulator gene. Hum Genet (1991) 1.03
The Walker B motif of the second nucleotide-binding domain (NBD2) of CFTR plays a key role in ATPase activity by the NBD1-NBD2 heterodimer. Biochem J (2007) 1.03
Development of an in vivo method to identify mutants of phage T4 lysozyme of enhanced thermostability. Protein Sci (1993) 1.02
Robustness of hen lysozyme monitored by random mutations. Protein Eng (2002) 0.80
A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. Genes Dev (2007) 5.83
ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer. Mol Cell (2002) 4.79
Gating of CFTR by the STAS domain of SLC26 transporters. Nat Cell Biol (2004) 3.43
Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J (2003) 3.35
Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc (2008) 3.19
The draft genome of a diploid cotton Gossypium raimondii. Nat Genet (2012) 3.18
Ubiquitin-induced oligomerization of the RNA sensors RIG-I and MDA5 activates antiviral innate immune response. Immunity (2012) 3.07
Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol (2008) 2.99
Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet (2013) 2.91
Hierarchical regulation of WASP/WAVE proteins. Mol Cell (2008) 2.86
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol (2009) 2.70
Cooperative, ATP-dependent association of the nucleotide binding cassettes during the catalytic cycle of ATP-binding cassette transporters. J Biol Chem (2002) 2.64
Recorded scan times can limit the accuracy of sedimentation coefficients in analytical ultracentrifugation. Anal Biochem (2013) 2.57
Endoproteolytic activity of the proteasome. Science (2002) 2.56
A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol (2012) 2.54
Side chain and backbone contributions of Phe508 to CFTR folding. Nat Struct Mol Biol (2004) 2.43
ATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasome. Mol Cell (2006) 2.26
A molecular mechanism for aberrant CFTR-dependent HCO(3)(-) transport in cystic fibrosis. EMBO J (2002) 2.11
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell (2012) 2.04
NaBC1 is a ubiquitous electrogenic Na+ -coupled borate transporter essential for cellular boron homeostasis and cell growth and proliferation. Mol Cell (2004) 2.02
CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices. Nat Struct Mol Biol (2007) 1.98
Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem (2001) 1.97
Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation. Chem Biol (2008) 1.97
High-precision isothermal titration calorimetry with automated peak-shape analysis. Anal Chem (2012) 1.92
A protein sequence that can encode native structure by disfavoring alternate conformations. Nat Struct Biol (2002) 1.85
Mechanism of actin filament nucleation by the bacterial effector VopL. Nat Struct Mol Biol (2011) 1.80
Coupling modes and stoichiometry of Cl-/HCO3- exchange by slc26a3 and slc26a6. J Gen Physiol (2006) 1.73
Arp2/3 complex is bound and activated by two WASP proteins. Proc Natl Acad Sci U S A (2011) 1.70
A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem (2005) 1.65
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol (2005) 1.65
Structural basis of histone demethylation by LSD1 revealed by suicide inactivation. Nat Struct Mol Biol (2007) 1.59
A segment of gamma ENaC mediates elastase activation of Na+ transport. J Gen Physiol (2007) 1.57
Slc26a6 regulates CFTR activity in vivo to determine pancreatic duct HCO3- secretion: relevance to cystic fibrosis. EMBO J (2006) 1.56
Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms. Proc Natl Acad Sci U S A (2006) 1.56
Gain-of-function mutation in TRPML3 causes the mouse Varitint-Waddler phenotype. J Biol Chem (2007) 1.56
Inhibition of chloride secretion in human bronchial epithelial cells by cigarette smoke extract. Am J Physiol Lung Cell Mol Physiol (2004) 1.56
Variability of myocardial ischemic responses to mental versus exercise or adenosine stress in patients with coronary artery disease. J Nucl Cardiol (2008) 1.55
Heart failure: comparison between six-minute walk test and cardiopulmonary test. Arq Bras Cardiol (2011) 1.55
The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J Biol Chem (2010) 1.55
Kinetic and structural insights into the mechanism of AMPylation by VopS Fic domain. J Biol Chem (2010) 1.51
Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model. Mov Disord (2012) 1.51
A TOG:αβ-tubulin complex structure reveals conformation-based mechanisms for a microtubule polymerase. Science (2012) 1.50
Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology (2009) 1.50
Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transpl (2007) 1.49
A novel mode of TRPML3 regulation by extracytosolic pH absent in the varitint-waddler phenotype. EMBO J (2008) 1.47
Complete genome sequence of the nitrogen-fixing and rhizosphere-associated bacterium Pseudomonas stutzeri strain DSM4166. J Bacteriol (2011) 1.46
Association of TLR4 gene non-missense single nucleotide polymorphisms with rheumatoid arthritis in Chinese Han population. Rheumatol Int (2012) 1.45
Congenital chloride-losing diarrhea causing mutations in the STAS domain result in misfolding and mistrafficking of SLC26A3. J Biol Chem (2008) 1.43
L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor. J Neurosci (2012) 1.43
Mental stress-induced myocardial ischemia in coronary artery disease patients with left ventricular dysfunction. J Nucl Cardiol (2007) 1.43
Changes at the KinA PAS-A dimerization interface influence histidine kinase function. Biochemistry (2008) 1.43
Repetitive oocyte donation does not decrease serum anti-Müllerian hormone levels. Fertil Steril (2009) 1.42
Overview of current methods in sedimentation velocity and sedimentation equilibrium analytical ultracentrifugation. Curr Protoc Protein Sci (2013) 1.41
Uncoupling retro-translocation and degradation in the ER-associated degradation of a soluble protein. EMBO J (2004) 1.38
Deletion of TRPC3 in mice reduces store-operated Ca2+ influx and the severity of acute pancreatitis. Gastroenterology (2009) 1.37
Fluid flow induces mechanosensitive ATP release, calcium signalling and Cl- transport in biliary epithelial cells through a PKCzeta-dependent pathway. J Physiol (2008) 1.36
Determination of protein complex stoichiometry through multisignal sedimentation velocity experiments. Anal Biochem (2010) 1.36
RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J Neurosci (2007) 1.35
A comparison of the tube forming potentials of early and late endothelial progenitor cells. Exp Cell Res (2007) 1.32
Transient receptor potential mucolipin 1 (TRPML1) and two-pore channels are functionally independent organellar ion channels. J Biol Chem (2011) 1.32
Interleukin-13 induces a hypersecretory ion transport phenotype in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol (2002) 1.31
S. aureus MscL is a pentamer in vivo but of variable stoichiometries in vitro: implications for detergent-solubilized membrane proteins. PLoS Biol (2010) 1.29
Dynamic control of cystic fibrosis transmembrane conductance regulator Cl(-)/HCO3(-) selectivity by external Cl(-). J Biol Chem (2004) 1.28
Retinopathy online challenge: automatic detection of microaneurysms in digital color fundus photographs. IEEE Trans Med Imaging (2009) 1.26
The torsin-family AAA+ protein OOC-5 contains a critical disulfide adjacent to Sensor-II that couples redox state to nucleotide binding. Mol Biol Cell (2008) 1.25
Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro. J Immunol (2010) 1.24
Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med (2010) 1.23
Organic solutes rescue the functional defect in delta F508 cystic fibrosis transmembrane conductance regulator. J Biol Chem (2003) 1.23
accordion, a zebrafish behavioral mutant, has a muscle relaxation defect due to a mutation in the ATPase Ca2+ pump SERCA1. Development (2004) 1.23
Effects of nickel, chromate, and arsenite on histone 3 lysine methylation. Toxicol Appl Pharmacol (2009) 1.23
A mind-body program for older adults with chronic low back pain: results of a pilot study. Pain Med (2009) 1.21
Neuronal regulation of pre-mRNA splicing by polypyrimidine tract binding proteins, PTBP1 and PTBP2. Crit Rev Biochem Mol Biol (2012) 1.20
Polarized but differential localization and recruitment of STIM1, Orai1 and TRPC channels in secretory cells. Traffic (2010) 1.20
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain (2008) 1.19
Identification and functional characterization of TMEM16A, a Ca2+-activated Cl- channel activated by extracellular nucleotides, in biliary epithelium. J Biol Chem (2010) 1.19
A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjögren's syndrome at 7q11.23. Nat Genet (2013) 1.19
IRBIT governs epithelial secretion in mice by antagonizing the WNK/SPAK kinase pathway. J Clin Invest (2011) 1.18
Peripheral blood fibrocytes: enhancement of wound healing by cell proliferation, re-epithelialization, contraction, and angiogenesis. Ann Surg (2011) 1.17
Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J Comput Aided Mol Des (2010) 1.17
The primary folding defect and rescue of ΔF508 CFTR emerge during translation of the mutant domain. PLoS One (2010) 1.17
Borate transport and cell growth and proliferation. Not only in plants. Cell Cycle (2005) 1.15
Conformational remodeling of proteasomal substrates by PA700, the 19 S regulatory complex of the 26 S proteasome. J Biol Chem (2002) 1.15
Building an understanding of cystic fibrosis on the foundation of ABC transporter structures. J Bioenerg Biomembr (2007) 1.14
An aqueous route to multicolor photoluminescent carbon dots using silica spheres as carriers. Angew Chem Int Ed Engl (2009) 1.14
Nickel compounds induce phosphorylation of histone H3 at serine 10 by activating JNK-MAPK pathway. Carcinogenesis (2008) 1.14
Evaluation of Dimebon in cellular model of Huntington's disease. Mol Neurodegener (2008) 1.14
Evaluation of cardiac involvement during dengue viral infection. Clin Infect Dis (2013) 1.13
Meta-analysis of the relationship between common type 2 diabetes risk gene variants with gestational diabetes mellitus. PLoS One (2012) 1.13
Multicomponent anthrax toxin display and delivery using bacteriophage T4. Vaccine (2006) 1.12
Modulation of histone methylation and MLH1 gene silencing by hexavalent chromium. Toxicol Appl Pharmacol (2009) 1.12
NMR evidence for differential phosphorylation-dependent interactions in WT and DeltaF508 CFTR. EMBO J (2009) 1.12
Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol Dis (2008) 1.12
Impact of the soak and the malt on the physicochemical properties of the sorghum starches. Int J Mol Sci (2010) 1.11
Control of hematopoietic stem cell emergence by antagonistic functions of ribosomal protein paralogs. Dev Cell (2013) 1.11
Crystal structure of the Tp34 (TP0971) lipoprotein of treponema pallidum: implications of its metal-bound state and affinity for human lactoferrin. J Biol Chem (2006) 1.10
Improving the thermal, radial, and temporal accuracy of the analytical ultracentrifuge through external references. Anal Biochem (2013) 1.10